Investigació

La Unitat de VIH i ITS porta a terme des de fa molts anys nombrosos estudis i assajos clínics, tant promoguts per la industria farmacèutica com projectes propis que han aconseguit ajudes econòmiques en convocatòries publiques competitives. Dins del nostre equip comptem amb 3 coordinadores d'assajos clinics i amb una estadistica per donar suport i desenvolupar  tots els projectes que realitzem a la nostra unitat.

Les línies d'investigació que es desenvolupen a la Unitat son les següents:

- Assaigs clínics fase I-IV i estudis post autorització amb antirretrovirals.

- Alteracions metabòliques, risc cardiovascular i aterosclerosis subclínica.

- Lipodistròfia en pacients infectats pel VIH.

 - Concentració i activitat antiviral dels medicaments antirretrovirals en reservoris corporals.

- Trastorns neurocognitius associats al VIH i eficàcia del tractament antirretroviral.

- Prevenció del càncer anal i prevalença del Virus del Papil·loma Humà en homes homosexual VIH+.

- Diagnòstic i tractament dels malalts VIH+ coinfectats pels Virus de la Hepatitis C i B.

- Evolució clínica i epidemiològica de la infecció pel VIH.

Actualment, amb l'objectiu de donar la millor atenció i amb el coneixement cientifci més actual, s'estàn duent a terme els següents estudis en la nostra Unitat:

Assajos clinics i projectes d'investigació finalitzats

  • Estudio SPRING-2 (ING113086). Estudio fase III, aleatorizado, doble ciego, para evaluar la eficacia y la seguridad de 50 mg de GSK 1349572 una vez al día, frente a 400 mg de raltegravir dos veces al día, ambos administrados con una combinación doble, a dosis fija, de inhibidores de la transcriptasa inversa análogos de los nucleósidos durante un periodo de 96 semanas en pacientes adultos infectados por el VIH-1 que no han recibido tratamiento antiretroviral previo”

  • SINGLE study. (ING114467). A Phase III, randomized, double-blind study of the safety and efficacy of GSK1349572 plus abacavir-lamivudine fixed-dose combination therapy administered once daily compared to Atripla over 96 weeks in HIV-1 infected antiretroviral therapy naive adult subjects

  • GS-US-236-0115 study. A Phase 3b Randomized, Open-Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor plus Emtricitabine/Tenofovir Fixed-Dose Combination (FTC/TDF) to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (EVG/COBI/FTC/TDF) in Virologically-Suppressed, HIV-1 Infected Patients.

  • FLAMINGO study. ING11915. A Phase IIIb, randomized, open-label study of the safety and efficacy of GSK1349572 (dolutegravir, DTG) 50 mg once daily compared to darunavir/ritonavir (DRV/r) 800 mg/100 mg once daily each administered with fixed-dose dual nucleoside reverse transcriptase inhibitor therapy over 96 weeks in HIV-1 infected antiretroviral naïve adult subjects

  • GS-US-2952-0109 study. A Phase 3, Open-Label Study to Evaluate Switching from a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects 

  • GS-US-292-0112 Study. A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients with Mild to Moderate Renal Impairment

    GS-US-292-0104 study. A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate in HIV 1 Positive, Antiretroviral Treatment- Naïve Adults

  • ARIA (ING117172 ) study. A Phase IIIb, randomized, open-label study of the safetyand efficacy of dolutegravir/abacavir/lamivudine once daily compared to atazanavir and ritonavir plus tenofovir/emtricitabine once daily in HIV-1 infected antiretroviral therapy naïve women

  • NEAT 22/SSAT 060 Study. An open label study examining the efficacy and safety (cardiovascular risk) of immediate versus deferred switch from a boosted PI to dolutegravir (DTG) in HIV infected patients with stable virological suppression

  • VIDEOS study.Dolutegravir HIV-1 viral decay and pharmacokinetics in semen in ARV-naïve patients initiating Abacavir/Lamivudine/Dolutegravir

Assajos clinics en marxa

  • TMC114IFD3013. EMERALD Study. Estudio de fase 3, aleatorizado, controlado con tratamiento activo y abierto para evaluar el cambio de tratamiento a un régimen en un solo comprimido administrado una vez al día de darunavir/cobicistat/emtricitabina/tenofovir alafenamida (D/C/F/TAF) frente a la continuación del régimen actual formado por un inhibidor de la proteasa potenciado (IPp) combinado con emtricitabina/tenofovir disoproxil  fumarato (FTC/TDF) en sujetos infectados por el virus de la inmunodeficiencia humana de tipo 1 (VIH-1) con supresión virológica

  •  

    TMC114FD2HTX3001. AMBER Study. Ensayo en fase 3, randomizado, controlado con tratamiento activo y doble ciego para evaluar la eficacia y seguridad del régimen combinado de darunavir/cobicistat/emtricitabina/tenofovir alafenamida (D/C/F/TAF) administrado una vez al día frente al régimen consistente en la combinación de darunavir/cobicistat coadministrado junto con la combinación emtricitabina/tenofovir disoproxil fumarato en sujetos naive en tratamiento antirretroviral infectados por el virus de la inmunodeficiencia humana de tipo 1

  •  

    SWORD-2 study (201637). A Phase III, randomized, multicenter, parallel-group, noninferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus rilpivirine from current INI-, NNRTI-, or PI-based antiretroviral regimen in HIV-1-infected adults who are virologically suppressed

  •  

    MK-1439A-021. Ensayo clínico de fase III multicéntrico, doble ciego, aleatorizado, controlado con producto activo para evaluar la seguridad y eficacia de MK-1439A administrado una vez al día frente a ATRIPLA™ administrado una vez al día en sujetos infectados por el VIH-1 sin tratamiento previo

  •  

    MK-1439-018. Ensayo clínico en fase III, multicéntrico, doble ciego, aleatorizado, controlado con un comparador activo para evaluar la seguridad y eficacia de 100 mg de doravirina (MK-1439) una vez al día frente a 800 mg de darunavir una vez al día más 100 mg de ritonavir una vez al día, cada uno de ellos en combinación con TRUVADA TM o EPZICOM TM/ KIVEXA TM, en sujetos infectados por el VIH-1 no tratados previamente

  •  

    GS-US-366-1216. A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects who are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)

  •  

    GS-US-366-1160 A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching from a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Subjects

  •  

    GS-US-311-1717. Estudio de fase 3b, aleatorizado, doble ciego, con cambio de tratamiento para evaluar F/TAF, en pacientes con infección por VIH-1 y supresión virológica que reciben tratamientos que contienen ABC/3TC

  •  

    ANRS 163 – ETRAL. Ensayo clínico no-comparativo fase II para evaluar la capacidad de la combinación dual raltegravir/etravirina para mantener la supresión virológica en pacientes infectados por el VIH-1 de al menos 45 años de edad con una carga viral plasmática VIH-RNA por debajo de 50 copias/mL en tratamiento con un régimen que incluya un inhibidor de la proteasa potenciado

  •  

    Institut National de la Santé et de la Recherche Médicale. Agence nationale de recherches sur le sida et les hépatites virales (Inserm – ANRS)

  •  

    ADVANZ4 study. Reconstitución inmune en pacientes con infección por el VIH-1 no tratados previamente y con cifras de linfocitos CD4+ inferiores a 100 céls/mm3 que reciben un régimen de fármacos antirretrovirales basado en dolutegravir o darunavir/ritonavir

  •  

    GS-US-380-1490. A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults

  •  

    GS-US-380-1489. A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults

  •  

    GS-US-380-1844. A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF in HIV-1 Infected Subjects who are Virologically Suppressed

  •  

    Estudio FLAIR. Estudio de fase 3, aleatorizado, multicéntrico, abierto, de grupos paralelos que evalúa la eficacia, seguridad y tolerabilidad de la administración de cabotegravir y rilpivirna de acción prolongada por vía intramuscular para el mantenimiento de la supresión virlógica tras el cambio a partir de un tratamiento de comprimido único con un inhibidor de la integrasa en participantes adultos con infección por VIH-1 que no han recibido un tratamiento previo con fármacos antrirretrovirales

  •  

    GS-US-412-2055. A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are at Risk of HIV-1 Infection

  •  

    ABX464-004. A multi-center, randomized, double-blind, placebo-controlled Phase II ato compare safety of ABX464 given at a fixed dose to placebo in fully controlled HIV infected patients treated with boosted protease inhibitor treatment (darunavir/ritonavir o darunavir/cobicistat)

Propers projectes

Durant el poper any iniciarem més projectes d'investigació dins de les següents linies:

  • - Millora i simplificació dels tractaments antirretroviral
  • - Reducció de les comorbiditats de la malaltia
  • - Estudi de l'acció de nous fàrmacs en reservoris del virus
  • - Estudi d'estratègies de prevenció pre-exposició
Articles publicats (2014-2018)

L'activitat científica que realitzem en la unitat ha generat la publicació en revistes d'alt impacte dels següents artícles:

  • 1: Orkin C, DeJesus E, Ramgopal M, Crofoot G, Ruane P, LaMarca A, Mills A, Vandercam B, de Wet J, Rockstroh J, Lazzarin A, Rijnders B, Podzamczer D, Thalme  A, Stoeckle M, Porter D, Liu HC, Cheng A, Quirk E, SenGupta D, Cao H. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection:  a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Lancet HIV. 2017 Mar 1. pii: S2352-3018(17)30031-0. doi: 10.1016/S2352-3018(17)30031-0. [Epub ahead of print] PubMed PMID: 28259777.

     

    2: Troya J, Ryan P, Ribera E, Podzamczer D, Hontañón V, Terrón JA, Boix V, Moreno S, Barrufet P, Castaño M, Carrero A, Galindo MJ, Suárez-Lozano I, Knobel H, Raffo M, Solís J, Yllescas M, Esteban H, González-García J, Berenguer J, Imaz A; GESIDA-8314 Study Group.. Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study. PLoS One. 2017 Feb 9;12(2):e0172184. doi: 10.1371/journal.pone.0172184. eCollection 2017. PubMed PMID: 28182783; PubMed Central PMCID: PMC5300180.

     

    3: Imaz A, Podzamczer D. Tenofovir alafenamide, emtricitabine, elvitegravir, and  cobicistat combination therapy for the treatment of HIV. Expert Rev Anti Infect Ther. 2017 Mar;15(3):195-209. doi: 10.1080/14787210.2017.1286736. Epub 2017 Feb 8. PubMed PMID: 28117606.

     

    4: Saumoy M, Tiraboschi JM, Ordoñez-Llanos J, Ribera E, Domingo P, Mallolas J, Curto J, Gatell JM, Podzamczer D. Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r: OLE-MET substudy. HIV Clin Trials. 2017 Mar;18(2):49-53. doi: 10.1080/15284336.2016.1275425. Epub 2017 Jan 12. PubMed PMID: 28081673.

     

     

    5: Imaz A, Martinez-Picado J, Niubó J, Kashuba AD, Ferrer E, Ouchi D, Sykes C, Rozas N, Acerete L, Curto J, Vila A, Podzamczer D. HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral  Regimen. J Infect Dis. 2016 Nov 15;214(10):1512-1519. Epub 2016 Aug 30. PubMed PMID: 27578849; PubMed Central PMCID: PMC5091371.

     

    6: Troya J, Ryan P, Ribera E, Podzamczer D, Hontañón V, Terrón JA, Boix V, Moreno S, Barrufet P, Castaño M, Carrero A, Galindo MJ, Suárez-Lozano I, Knobel H, Raffo M, Solís J, Yllescas M, Esteban H, González-García J, Berenguer J, Imaz A; GESIDA-8314 Study Group.. Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study. PLoS One. 2016 Oct 11;11(10):e0164455. doi: 10.1371/journal.pone.0164455. eCollection 2016. Erratum in: PLoS One. 2017 Feb 9;12 (2):e0172184. PubMed PMID: 27727331; PubMed Central PMCID: PMC5058546.

     

    7: Llibre JM, de Lazzari E, Molina JM, Gallien S, Gonzalez-García J, Imaz A, Podzamczer D, Clotet B, Domingo P, Gatell JM. Cost-effectiveness of initial antiretroviral treatment administered as single vs. multiple tablet regimens with the same or different components. Enferm Infecc Microbiol Clin. 2016 Aug 29. pii: S0213-005X(16)30236-1. doi: 10.1016/j.eimc.2016.07.006. [Epub ahead of print] PubMed PMID: 27595183.

     

    8: Curran A, Rojas J, Cabello A, Troya J, Imaz A, Domingo P, Martinez E, Ryan P,  Górgolas M, Podzamczer D, Knobel H, Gutiérrez F, Ribera E. Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patients. J Antimicrob Chemother. 2016 Dec;71(12):3510-3514. Epub 2016 Sep 2. PubMed PMID: 27591292.

     

    9: Cuervo G, Simonetti AF, Alegre O, Sanchez-Salado JC, Podzamczer D. Toxoplasma myocarditis: a rare but serious complication in an HIV-infected late presenter. AIDS. 2016 Sep 10;30(14):2253-4. doi: 10.1097/QAD.0000000000001174. PubMed PMID: 27574795.

     

    10: Podzamczer D, Imaz A. Dual antiretroviral therapy: finding a place in the battle. Lancet HIV. 2016 Aug;3(8):e335-6. doi: 10.1016/S2352-3018(16)30021-2. Epub 2016 May 31. PubMed PMID: 27470021.

     

    11: Saumoy M, Llibre JM, Terrón A, Knobel H, Arribas JR, Domingo P, Arroyo-Manzano D, Rivero A, Moreno S, Podzamczer D. Short Communication: Maraviroc Once-Daily: Experience in Routine Clinical Practice. AIDS Res Hum Retroviruses. 2017 Jan;33(1):29-32. doi: 10.1089/AID.2015.0386. Epub 2016 Dec 20. PubMed PMID: 27250802.

     

    12: Nicolás D, Esteve A, Cuadros A, Campbell CN, Tural C, Podzamczer D, Murillas  J, Homar F, Segura F, Force L, Vilaró J, Masabeu À, Garcia I, Mercadal J, Montoliu A, Ferrer E, Riera M, Cifuentes C, Ambrosioni J, Navarro G, Manzardo C, Clotet B, Gatell JM, Casabona J, Miró JM; PISCIS Cohort Study Investigators.. Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients With HIV Infection or HIV/Hepatitis C Virus Coinfection. Clin Infect Dis. 2016 Jun 15;62(12):1578-85. doi: 10.1093/cid/ciw157. Epub 2016 Apr 28. PubMed PMID: 27126346.

     

    13: Iribarren JA, Rubio R, Aguirrebengoa K, Arribas JR, Baraia-Etxaburu J, Gutiérrez F, Lopez Bernaldo de Quirós JC, Losa JE, Miró JM, Moreno S, Pérez Molina J, Podzamczer D, Pulido F, Riera M, Rivero A, Sanz Moreno J, Amador C, Antela A, Arazo P, Arrizabalaga J, Bachiller P, Barros C, Berenguer J, Caylá J, Domingo P, Estrada V, Knobel H, Locutura J, López Aldeguer J, Llibre JM, Lozano F, Mallolas J, Malmierca E, Miralles C, Miralles P, Muñoz A, Ocampo A, Olalla J, Pérez I, Pérez Elías MJ, Pérez Arellano JL, Portilla J, Ribera E, Rodríguez F, Santín M, Sanz Sanz J, Téllez MJ, Torralba M, Valencia E, Von Wichmann MA; GESIDA/SEIMC Writing Committee.. Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015. Enferm Infecc Microbiol Clin. 2016 Oct;34(8):517-23. doi: 10.1016/j.eimc.2016.02.025. Epub 2016 Apr 5. PubMed PMID: 27056581.

     

    14: Iribarren JA, Rubio R, Aguirrebengoa K, Arribas JR, Baraia-Etxaburu J, Gutiérrez F, Lopez Bernaldo de Quirós JC, Losa JE, Miró JM, Moreno S, Pérez Molina J, Podzamczer D, Pulido F, Riera M, Rivero A, Sanz Moreno J, Amador C, Antela A, Arazo P, Arrizabalaga J, Bachiller P, Barros C, Berenguer J, Caylá J, Domingo P, Estrada V, Knobel H, Locutura J, López Aldeguer J, Llibre JM, Lozano F, Mallolas J, Malmierca E, Miralles C, Miralles P, Muñoz A, Ocampo A, Olalla J,  Pérez I, Pérez Elías MJ, Pérez Arellano JL, Portilla J, Ribera E, Rodríguez F, Santín M, Sanz Sanz J, Téllez MJ, Torralba M, Valencia E, Von Wichmann MA; GESIDA/SEIMC Writing Committee.. Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015. Enferm Infecc Microbiol Clin. 2016 Oct;34(8):516.e1-516.e18. doi: 10.1016/j.eimc.2016.02.004. Epub 2016 Mar 11. PubMed PMID: 26976381.

    15: Dinges W, Girard PM, Podzamczer D, Brockmeyer NH, García F, Harrer T, Lelievre JD, Frank I, Colin De Verdière N, Yeni GP, Ortega Gonzalez E, Rubio R, Clotet Sala B, DeJesus E, Pérez-Elias MJ, Launay O, Pialoux G, Slim J, Weiss L, Bouchaud O, Felizarta F, Meurer A, Raffi F, Esser S, Katlama C, Koletar SL, Mounzer K, Swindells S, Baxter JD, Schneider S, Chas J, Molina JM, Koutsoukos M,  Collard A, Bourguignon P, Roman F. The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial. Medicine (Baltimore). 2016 Feb;95(6):e2673. doi: 10.1097/MD.0000000000002673. PubMed PMID: 26871794; PubMed Central PMCID: PMC4753889.

     

     

    16: Saumoy M, Alonso-Villaverde C, Navarro A, Olmo M, Vila R, Ramon JM, Di Yacovo S, Ferrer E, Curto J, Vernet A, Vila A, Podzamczer D. Randomized trial of a multidisciplinary lifestyle intervention in HIV-infected patients with moderate-high cardiovascular risk. Atherosclerosis. 2016 Mar;246:301-8. doi: 10.1016/j.atherosclerosis.2016.01.014. Epub 2016 Jan 11. PubMed PMID: 26826629.

     

    17: Tiraboschi JM, Knobel H, Imaz A, Villar J, Ferrer E, Saumoy M, González A, Rozas N, Vila A, Niubó J, Curto J, Podzamczer D. Cerebrospinal fluid and plasma lopinavir concentrations and viral response in virologically suppressed patients  switching to lopinavir/ritonavir monotherapy once daily. Antivir Ther. 2016;21(4):359-63. doi: 10.3851/IMP3015. Epub 2015 Dec 14. PubMed PMID: 26656921.

     

    18: Ferrer E, Curto J, Esteve A, Miro JM, Tural C, Murillas J, Segura F, Barrufet P, Casabona J, Podzamczer D; PISCIS Investigators.. Clinical progression of severely immunosuppressed HIV-infected patients depends on virological and immunological improvement irrespective of baseline status. J Antimicrob

    Chemother. 2015 Dec;70(12):3332-8. doi: 10.1093/jac/dkv272. Epub 2015 Sep 25. PubMed PMID: 26410171.

     

    19: Berenguer J, Rivero A, Blasco AJ, Arribas JR, Boix V, Clotet B, Domingo P, González-García J, Knobel H, Lázaro P, López JC, Llibre JM, Lozano F, Miró JM, Podzamczer D, Tuset M, Gatell JM; GeSIDA Antiretroviral Therapy Cost-efficacy Study Group.. Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. Enferm Infecc Microbiol Clin. 2016 Jun-Jul;34(6):361-71. doi: 10.1016/j.eimc.2015.07.012. Epub 2015 Aug 28. PubMed PMID: 26321131.

     

    20: Velasco C, Pérez I, Podzamczer D, Llibre JM, Domingo P, González-García J, Puig I, Ayala P, Martín M, Trilla A, Lázaro P, Gatell JM. Prediction of higher cost of antiretroviral therapy (ART) according to clinical complexity. A validated clinical index. Enferm Infecc Microbiol Clin. 2016 Mar;34(3):149-58. doi: 10.1016/j.eimc.2015.07.009. Epub 2015 Aug 20. PubMed PMID: 26298097.

     

    21: Walmsley S, Baumgarten A, Berenguer J, Felizarta F, Florence E, Khuong-Josses MA, Kilby JM, Lutz T, Podzamczer D, Portilla J, Roth N, Wong D, Granier C, Wynne B, Pappa K. Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial. J Acquir Immune Defic Syndr. 2015 Dec 15;70(5):515-9. doi: 10.1097/QAI.0000000000000790. Erratum in: J Acquir Immune Defic Syndr. 2016 Jan 1;71(1):e33. PubMed PMID: 26262777; PubMed Central PMCID: PMC4645960.

     

    22: Casadellà M, Manzardo C, Noguera-Julian M, Ferrer E, Domingo P, Pérez-Álvarez S, Podzamczer D, Plana M, Clotet B, Gatell JM, Miró JM, Paredes R; ADVANZ and ADVANZ-3 Investigators.. Clinical value of ultradeep HIV-1 genotyping and tropism testing in late presenters with advanced disease. AIDS. 2015 Jul 31;29(12):1493-504. doi: 10.1097/QAD.0000000000000748. PubMed PMID: 26244389.

     

    23: Imaz A, Camoez M, Di Yacovo S, Gasch O, Dominguez MA, Vila A, Maso-Serra M, Pujol M, Podzamczer D. Prevalence of methicillin-resistant Staphylococcus aureus colonization in HIV-infected patients in Barcelona, Spain: a cross-sectional study. BMC Infect Dis. 2015 Jun 26;15:243. doi: 10.1186/s12879-015-0991-z. PubMed PMID: 26113228; PubMed Central PMCID: PMC4482197.

     

    24: Arribas JR, Girard PM, Landman R, Pich J, Mallolas J, Martínez-Rebollar M, Zamora FX, Estrada V, Crespo M, Podzamczer D, Portilla J, Dronda F, Iribarren JA, Domingo P, Pulido F, Montero M, Knobel H, Cabié A, Weiss L, Gatell JM; OLE/RIS-EST13 Study Group.. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. Lancet Infect Dis. 2015 Jul;15(7):785-92. doi: 10.1016/S1473-3099(15)00096-1. Epub 2015 Jun 7. Erratum in: Lancet Infect Dis. 2015 Aug;15(8):875. PubMed PMID: 26062880.

     

    25: Expert Panel of GESIDA and the National AIDS Plan., Berenguer J, Polo R, Aldeguer JL, Lozano F, Aguirrebengoa K, Arribas JR, Blanco JR, Boix V, Casado JL, Clotet B, Crespo M, Domingo P, Estrada V, García F, Gatell JM, González-García J, Gutiérrez F, Iribarren JA, Knobel H, Llibre JM, Locutura J, López JC, Miró JM, Moreno S, Podzamczer D, Portilla J, Pulido F, Ribera E, Riera M, Rubio R, Santos J, Sanz-Moreno J, Sanz J, Téllez MJ, Tuset M, Rivero A. Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015). Enferm Infecc Microbiol Clin. 2015 Oct;33(8):544-56. doi: 10.1016/j.eimc.2015.03.017. Epub 2015 May 26. PubMed PMID: 26021186.

     

    26: Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, Pozniak A, Thompson M, Podzamczer D, Molina JM, Oka S, Koenig E, Trottier B, Andrade-Villanueva J, Crofoot G, Custodio JM, Plummer A, Zhong L, Cao H, Martin H, Callebaut C, Cheng AK, Fordyce MW, McCallister S; GS-US-292-0104/0111 Study Team.. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015 Jun 27;385(9987):2606-15. doi: 10.1016/S0140-6736(15)60616-X. Epub 2015 Apr 15. Erratum in: Lancet. 2016 Apr 30;387(10030):1816. PubMed PMID: 25890673.

     

    27: Santos JR, Saumoy M, Curran A, Bravo I, Llibre JM, Navarro J, Estany C, Podzamczer D, Ribera E, Negredo E, Clotet B, Paredes R; Tenofovir/emtricitabine inflUence on LIPid metabolism (TULIP) Study Group.. The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial. Clin Infect Dis. 2015 Aug 1;61(3):403-8. doi: 10.1093/cid/civ296. Epub 2015 Apr 13. PubMed PMID: 25870325.

     

    28: Ribera E, Podzamczer D. [Mechanisms of action, pharmacology and interactions  of dolutegravir]. Enferm Infecc Microbiol Clin. 2015 Mar;33 Suppl 1:2-8. doi: 10.1016/S0213-005X(15)30002-1. Review. Spanish. PubMed PMID: 25858605.

     

    29: Miro JM, Manzardo C, Ferrer E, Loncà M, Guardo AC, Podzamczer D, Domingo P, Curran A, Clotet B, Cruceta A, Lozano F, Pérez I, Plana M, Gatell JM; Advanz-3 Study Group.. Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial). J Acquir Immune Defic Syndr. 2015 Jun 1;69(2):206-15. doi: 10.1097/QAI.0000000000000567. PubMed PMID: 25831464.

     

    30: Van den Eynde E, Curto J, Ferrer E, Imaz A, Saumoy M, Di Yacovo S, Vila A, Podzamczer D. Telaprevir decreases estimated glomerular filtration rate in HIV-hepatitis C virus coinfected patients. AIDS. 2015 May 15;29(8):977-9. doi: 10.1097/QAD.0000000000000643. PubMed PMID: 25784438.

     

    31: Di Yacovo MS, Moltó J, Ferrer E, Curran A, Else L, Gisslén M, Clotet B, Tiraboschi JM, Niubò J, Vila A, Zetterberg H, Back D, Podzamczer D. Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression. J Antimicrob Chemother. 2015 May;70(5):1513-6. doi: 10.1093/jac/dku558. Epub 2015 Jan 20. PubMed PMID: 25608583.

     

    32: Viciana-Fernández P, Falcó V, Castaño M, de los Santos-Gil I, Olalla-Sierra J, Hernando A, Deig E, Clotet B, Knobel H, Podzamczer D, Pedrol PD; Grupo de trabajo Bridgap.. [Barriers to ART initiation in HIV infected subjects and with treatment indication in Spain. Why don't they start their treatment? Bridgap Study]. Enferm Infecc Microbiol Clin. 2015 Jun-Jul;33(6):397-403. doi: 10.1016/j.eimc.2014.06.012. Epub 2015 Jan 7. Spanish. PubMed PMID: 25577557.

     

    33: Saumoy M, Ordóñez-Llanos J, Martínez E, Ferrer E, Domingo P, Ribera E, Negredo E, Curto J, Sánchez-Quesada JL, Di Yacovo S, González-Cordón A, Podzamczer D. Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: a substudy of the ATADAR randomized study. J Antimicrob Chemother. 2015 Apr;70(4):1130-8. doi: 10.1093/jac/dku501. Epub 2014 Dec 23. PubMed PMID: 25538166.

     

    34: Moltó J, Valle M, Ferrer E, Domingo P, Curran A, Santos JR, Mateo MG, Di Yacovo MS, Miranda C, Podzamczer D, Clotet B; DRV600 Study Group.. Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial. J Antimicrob Chemother. 2015 Apr;70(4):1139-45. doi: 10.1093/jac/dku516. Epub 2014 Dec 18. PubMed PMID: 25525195.

     

    35: Di Yacovo S, Molto J, Ferrer E, Curran A, Else LJ, Clotet B, Tiraboschi J, Niubo J, Vila A, Podzamczer D. DRV concentrations and viral load in CSF in patients on DRV/r 600/100 or 800/100mg once daily plus two NRTI. J Int AIDS Soc.  2014 Nov 2;17(4 Suppl 3):19821. doi: 10.7448/IAS.17.4.19821. eCollection 2014. PubMed PMID: 25397565; PubMed Central PMCID: PMC4225360.

     

    36: Podzamczer D, Rozas N, Domingo P, Ocampo A, Van den Eynde E, Deig E, Vergara  A, Knobel H, Pasquau J, Antela A, Crespo M, Clotet B, Muñoz J, Fernandez P, Geijo P, de Castro ER, Diz J, Casado A, Torres C. ACTG-HIV symptoms changes in patients switched to RPV/FTC/TDF due to previous intolerance to CART. Interim analysis of the PRO-STR study. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19814. doi: 10.7448/IAS.17.4.19814. eCollection 2014. PubMed PMID: 25397558; PubMed Central PMCID: PMC4225323.

     

    37: Podzamczer D, Rojas JF, Neves I, Ferrer E, Llibre JM, Leal M, Gorgolas M, Jose CM, Gatell JM, Abreu RC, Curto J, Domingo P, Pilar BM, Rozas N. Effectiveness and tolerability of abacavir-lamivudine-nevirapine (ABC/3TC/NVP) in a multicentre cohort of HIV-infected, ARV-naïve patients. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19773. doi: 10.7448/IAS.17.4.19773. eCollection 2014. PubMed PMID: 25397517; PubMed Central PMCID: PMC4225404.

     

    38: Tiraboschi J, Imaz A, Ferrer E, Saumoy M, Rozas N, Maso M, Vila A, Niubo J, Podzamczer D. CSF LPV concentrations and viral load in viral suppressed patients  on LPV/r monotherapy given once daily. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19587. doi: 10.7448/IAS.17.4.19587. eCollection 2014. PubMed PMID: 25394093; PubMed Central PMCID: PMC4224921.

     

    39: Ferrer E, Navarro A, Curto J, Medina P, Rozas N, Barrera G, Saumoy M, Tiraboschi JM, Gomez C, Podzamczer D. Long-term fat redistribution in ARV-naïve HIV+ patients initiating a non-thymidine containing regimen in clinical practice. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19553. doi: 10.7448/IAS.17.4.19553. eCollection 2014. PubMed PMID: 25394060; PubMed Central PMCID: PMC4224890.

     

    40: Santos JR, Saumoy M, Curran A, Bravo I, Navarro J, Estany C, Podzamczer D, Ribera E, Negredo E, Clotet B, Paredes R. Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19550. doi: 10.7448/IAS.17.4.19550. eCollection 2014. PubMed PMID: 25394057; PubMed Central PMCID: PMC4224859.

     

    41: Martinez E, Gonzalez-Cordon A, Ferrer E, Domingo P, Negredo E, Gutierrez F, Portilla J, Curran A, Podzamczer D, Ribera E, Murillas J, Bernardino JI, Santos I, Carton JA, Peraire J, Pich J, Deulofeu R, Perez I, Gatell JM; ATADAR Study Group.. Differential body composition effects of protease inhibitors recommended  for initial treatment of HIV infection: a randomized clinical trial. Clin Infect Dis. 2015 Mar 1;60(5):811-20. doi: 10.1093/cid/ciu898. Epub 2014 Nov 10. PubMed PMID: 25389256.

     

    42: Blasco AJ, Llibre JM, Berenguer J, González-García J, Knobel H, Lozano F, Podzamczer D, Pulido F, Rivero A, Tuset M, Lázaro P, Gatell JM; GESIDA ART Cost-efficacy Study Group.. Costs and cost-efficacy analysis of the 2014 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. Enferm Infecc Microbiol Clin. 2015 Mar;33(3):156-65. doi: 10.1016/j.eimc.2014.05.016. Epub 2014 Aug 28. PubMed PMID: 25175171.

     

    43: Imaz A, Cayuela N, Niubó J, Tiraboschi JM, Izquierdo C, Cabellos C, Podzamczer D. Short communication: focal encephalitis related to viral escape and resistance emergence in cerebrospinal fluid in a patient on lopinavir/ritonavir monotherapy with plasma HIV-1 RNA suppression. AIDS Res Hum Retroviruses. 2014 Oct;30(10):984-7. doi: 10.1089/AID.2014.0014. Epub 2014 Sep 8. PubMed PMID: 25096495.

     

    44: Van den Eynde E, Podzamczer D. Switch strategies in antiretroviral therapy regimens. Expert Rev Anti Infect Ther. 2014 Sep;12(9):1055-74. doi:10.1586/14787210.2014.944506. Epub 2014 Jul 30. Review. PubMed PMID: 25075752.

     

    45: Expert Panel of GeSIDA and the National Aids Plan., Berenguer J, Polo R, Lozano F, López Aldeguer J, Antela A, Arribas JR, Asensi V, Blanco JR, Clotet B, Domingo P, Galindo MJ, Gatell JM, González-García J, Iribarren JA, Locutura J, López JC, Mallolas J, Martínez E, Miralles C, Miró JM, Moreno S, Palacios R, Pérez Elías MJ, Pineda JA, Podzamczer D, Portilla J, Pulido F, Ribera E, Riera M, Rubio R, Santos J, Sanz J, Tuset M, Vidal F, Rivero A. Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults  infected by the human immunodeficiency virus (updated January 2014). Enferm Infecc Microbiol Clin. 2014 Aug-Sep;32(7):447-58. doi: 10.1016/j.eimc.2014.02.018. Epub 2014 Jun 28. PubMed PMID: 24986715.

     

    46: Blanco JL, Gonzalez-Cordón A, Llibre JM, Calvo M, Gutierrez F, Podzamczer D, Laguno M, Fumero E, Murillas J, Mallolas J, Martinez-Rebollar M, Lonca M, Perez I, Gatell JM, Martinez E. Impact of prior virological failure and nucleos(t)ide genotypic resistance mutations on the efficacy of switching from ritonavir-boosted protease inhibitors to raltegravir. Antivir Ther. 2015;20(5):487-92. doi: 10.3851/IMP2812. Epub 2014 Jun 25. PubMed PMID: 24964358.

     

    47: Caniglia EC, Cain LE, Justice A, Tate J, Logan R, Sabin C, Winston A, van Sighem A, Miro JM, Podzamczer D, Olson A, Arribas JR, Moreno S, Meyer L, del Romero J, Dabis F, Bucher HC, Wandeler G, Vourli G, Skoutelis A, Lanoy E, Gasnault J, Costagliola D, Hernán MA; HIV-CAUSAL Collaboration. Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. Neurology. 2014 Jul 8;83(2):134-41. doi: 10.1212/WNL.0000000000000564. Epub 2014  Jun 6. PubMed PMID: 24907236; PubMed Central PMCID: PMC4117168.

     

    48: Van den Eynde E, Ferrer E, Podzamczer D. Acute renal failure and liver toxicity in an HIV/hepatitis C coinfected patient receiving telaprevir and boosted atazanavir. AIDS. 2014 Jun 19;28(10):1538-9. doi: 10.1097/QAD.0000000000000265. PubMed PMID: 24896804.

     

    49: Pollard RB, Rockstroh JK, Pantaleo G, Asmuth DM, Peters B, Lazzarin A, Garcia F, Ellefsen K, Podzamczer D, van Lunzen J, Arastéh K, Schürmann D, Clotet B, Hardy WD, Mitsuyasu R, Moyle G, Plettenberg A, Fisher M, Fätkenheuer G, Fischl M, Taiwo B, Baksaas I, Jolliffe D, Persson S, Jelmert O, Hovden AO, Sommerfelt MA, Wendel-Hansen V, Sørensen B. Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2014 Apr;14(4):291-300. doi: 10.1016/S1473-3099(13)70343-8. Epub 2014 Feb 11. PubMed PMID: 24525316.

     

    50: Imaz A, Llibre JM, Navarro J, Curto J, Clotet B, Crespo M, Ferrer E, Saumoy M, Tiraboschi JM, Murillo O, Podzamczer D. Effectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/ml. Antivir Ther. 2014;19(6):569-77. doi: 10.3851/IMP2736. Epub 2014 Jan 23. PubMed PMID: 24458091.

     

    51: Curran A, Monteiro P, Domingo P, Villar J, Imaz A, Martínez E, Fernández I, Knobel H, Podzamczer D, Iribarren JA, Peñaranda M, Crespo M; PIMOCS Study Group. Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group. J Antimicrob Chemother. 2014 May;69(5):1390-6. doi: 10.1093/jac/dkt517. Epub 2014 Jan 10. PubMed PMID: 24415645.

     

    52: Short Communication: Lack of Effect of Maraviroc Intensification on Blood and Gut Reservoir.

    Tiraboschi J, Ray S, Patel K, Pace M, Phalora P, Robinson N, Hopkins E, Meyerowitz J, Wang Y, Davies O, Mant C, Cason J, Kaye S, Sanderson J, Fidler S, Klenerman P, Frater J, Fox J. AIDS Res Hum Retroviruses. 2017 Feb;33(2):143-146

     

    53: Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis. Fox J, Tiraboschi JM, Herrera C, Else L, Egan D, Dickinson L, Jackson A, Olejniczak N, Back D, Khoo S, Shattock R, Boffito M. J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):252-257.

     

    54: Short Communication: The Impact of Switching from Atripla to Darunavir/Ritonavir Monotherapy on Neurocognition, Quality of Life, and Sleep: Results from a Randomized Controlled Study. Tiraboschi J, Hamzah L, Teague A, Kulasegaram R, Post F, Jendruleck I, Murray T, Fox J. AIDS Res Hum Retroviruses. 2016 Dec;32(12):1198-1201. Epub 2016 Aug 22.

     

    55: Cerebrospinal fluid viral escape and acute encephalitis in a patient on boosted protease inhibitor monotherapy. Tiraboschi J, Hamzah L, Siddiqui A, Kulasegaram R, Post F, Fox J. Antivir Ther. 2016;21(5):461-4

     

    56: Effects on vitamin D, bone and the kidney of switching from fixed-dose tenofovir disoproxil fumarate/emtricitabine/efavirenz to darunavir/ritonavir monotherapy: a randomized, controlled trial (MIDAS). Hamzah L, Tiraboschi JM, Iveson H, Toby M, Mant C, Cason J, Burling K, Wandolo E, Jendrulek I, Taylor C, Ibrahim F, Kulasegaram R, Teague A, Post FA, Fox J. Antivir Ther. 2016;21(4):287-96. doi: 10.3851/IMP3000. Epub 2015 Oct 13.

     

    57: Gonzalez FA, Van den Eynde E, Perez-Hoyos S, Navarro J, Curran A, Burgos J et al. Liver stiffness and aspartate aminotransferase levels predict the risk for liver fibrosis progression in hepatitis C virus/HIV-co-infected patients.  HIV Med, 2015. 16(4):211-8.

     

    58: Rojas J, Lonca M, Imaz A, Estrada V, Asens V, Miralles C et al. Improvement of lipoatrophy by switching from efavirenz to lopinar/ritonavir. HIV Med, 2016. 17(5):340-9.

     

    59: Poveda A, Hernandez-Quero J, Perez-Elías MJ, Ribas MA, Martinez Madrid OJ, Flores J et al. Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study. HIV Med. 2016 Dec 30: 10.111/hiv.12479

     

    60: De Luca A, Flandre P, Dunn D, Wensing A, Santoro MM, Günthard HF et al. Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and

    non-subtype B receiving a salvage regimen. J Antimicrob Chemother. 2016. 71(5):1352-60.

     

    61: Llibre JM, Alvarez H, Antela A, Toro J, Payeras A, Pérez-Elías MJ et al. Withdrawing inactive NRTIs in HIV-1 subjects with suppressed viraemia: a randomized trial. J Antimicrob Chemother. 2016. 71(5):1346-51.